Feb 24, 2026 07:30AM
Feb 17, 2026 08:05AM
Jan 12, 2026 08:07AM
Jan 12, 2026 08:05AM
Nov 24, 2025 08:06AM
Nov 24, 2025 08:05AM
Nov 19, 2025 08:05AM Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Nov 4, 2025 07:30AM
Oct 23, 2025 08:05AM
Oct 23, 2025 08:05AM
Aug 5, 2025 07:30AM
Aug 5, 2025 07:30AM
Jun 11, 2025 08:06AM
Jun 11, 2025 08:05AM Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
Jun 5, 2025 08:06AM
Jun 5, 2025 08:05AM
May 6, 2025 07:30AM
Apr 8, 2025 08:05AM
Apr 8, 2025 08:05AM
Mar 24, 2025 08:05AM
Mar 24, 2025 08:05AM Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
Feb 25, 2025 07:30AM
Feb 19, 2025 08:05AM
Feb 19, 2025 08:05AM
Jan 13, 2025 08:17AM
Jan 13, 2025 08:05AM
Oct 29, 2024 07:30AM
Aug 6, 2024 07:30AM Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
Aug 6, 2024 07:30AM
Jun 25, 2024 08:09AM
Jun 25, 2024 08:05AM
Jun 24, 2024 07:03AM
Jun 24, 2024 07:00AM
Jun 5, 2024 08:06AM
Jun 5, 2024 08:05AM HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
May 1, 2024 07:15AM
Apr 30, 2024 12:17PM
Apr 30, 2024 07:08AM
Apr 30, 2024 07:05AM
Apr 30, 2024 07:00AM
Apr 11, 2024 08:05AM
Apr 3, 2024 08:05AM Harmony Biosciences (HRMY) Commences Phase 3 TEMPO Study
Apr 3, 2024 08:05AM
Feb 22, 2024 07:30AM
Feb 21, 2024 08:06AM
Feb 21, 2024 08:05AM
Feb 20, 2024 08:05AM
Feb 20, 2024 08:05AM
Jan 8, 2024 08:17AM Harmony Biosciences (HRMY) Preliminary Unaudited Fourth Quarter And Full Year 2023 Net Product Revenue Increases
Jan 8, 2024 08:05AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All